Pyxis Oncology (PYXS) News
NASDAQ: PYXSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.81+0.13 (+7.74%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PYXS news summary
We found 4 recent headlines mentioning Pyxis Oncology (PYXS): 2 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. PYXS is making an outsized move today, up 7.74% at $1.81, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Pyxis Oncology Announces Updated MICVO Phase 1 Monotherapy Data in 2L+ R/M HNSCC", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pyxis Oncology headlines
- Pyxis Oncology Announces Updated MICVO Phase 1 Monotherapy Data in 2L+ R/M HNSCCPyxis Oncology, Inc. announced updated results from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic…NasdaqPYXS, HEI.A
- Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR SymposiumUpdated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 monthsGlobeNewswire
- Pyxis Oncology to Participate in Upcoming Investor ConferencesBOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that…GlobeNewswire
- Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a…GlobeNewswire